Rapidly mutating HIV-1 virus can continue to evade quantification with a single target viral load assay. The innovative dual target HIV-1 assay from Roche Molecular Diagnostics measures two unique regions of the HIV-1 genome, which are not subject to selective drug pressure. Therefore drug-induced mutations should not impact the assay’s ability to detect and quantify the virus accurately. In turn, more accurate results drive better decisions for a positive impact on patients’ lives.

Visit us at www.dual-target.com and ask for more information about the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0.